Health Biotechnology

Development of MEDICINES, NUTRACEUTICALS and BIOPRODUCTS

APPLICATION OF BIOMEDICAL BIOTECHNOLOGY IN THE DEVELOPMENT OF BIOACTIVE PRODUCTS

Development of Medicines, Nutraceuticals and Bioproducts

Ebiotec’s preclinical research team develops integral biological systems for the testing, in cell and animal models of various pathologies, of new bioactive compounds, their biochemical efficacy and their toxicity indices.

Screening in cell cultures

A drug toxicity analysis is performed in cell models with a high sensitivity to toxicity, enabling a more dependable extrapolation of the results. Besides, cell cultures can be used to identify the bioactive efficacy of compounds for the subsequent phase of studies in animals.

Human cancer cell screening panel

Our panel includes the following cell lines: HL-60 (leukemia), HS 274.T, HS 281T (breast adenocarcinoma), HS 313.T (lymphoma), H2126 (lung adenocarcinoma), WM 115 (melanoma), Caco-2 (colorectal carcinoma), HT-29 and SW-480 (colon carcinoma).

Screening in animal models

Traditional preclinical screening of drugs, nutraceuticals or bioproducts is performed in animal models, as these are simple to use and enable the obtaining of reproducible results, providing the necessary basic knowledge for the identification of pathological mechanisms in humans. Alzheimer’s disease animal models (e.g. APP/PS1/APO4); Parkinson’s disease animal models (e.g. Prnp-SNCA*A53T); Colorectal adenocarcinoma animal models (e.g. DSS)

Development of new animal models

Ebiotec’s biotechnological research center, in cooperation with international biotechnological centers, develops new transgenic models of the principal human diseases, as these are excellent animal models to study gene function and regulation in the search for new therapeutic strategies. Furthermore, they are bioreactors capable of generating bioactive sub-products for the treatment of diseases.

Proteomic
Studies

Identification of target proteins for biomedical therapy

Proteomics is the science that studies proteomes, which are sets of proteins expressed by a genome, in order to obtain a global, integrated view of cellular processes.

Development of proteomic analyses

Proteomics has a huge potential in the field of biomedicine, for use in:
– Methods of early diagnosis
– Design of alternative therapies
– Identification of target proteins
– Development of drugs
– Pathogenesis studies

– Estudios de patogénesis

Screening of target proteins

Identification of proteins of interest is performed by: mass spectrometry, two-dimensional electrophoresis, or liquid chromatography (proteome separation and analysis). Furthermore, our team is at the forefront of biomedical research applied to the implementation, development and standardization of new proteomic techniques, and the development and characterization of new bioactive molecules (toxins, poisons, vaccines).


Genic Expression
Analysis

Genic expression analysis in biomedicine

The genetic code stored in DNA is “read” by gene expression, and the properties of said expression give rise to the organism’s phenotype. These phenotypes are often expressed by the synthesis of proteins which control the form of the organism, or which act as enzymes to catalyze the specific metabolic pathways which characterize it.

Characterization of gene expression in biological samples

Identification of the temporal pattern of cellular gene expression at a particular stage of biological development enables us to identify the functional and proteomic changes which give rise to the pathological effects diagnosed. Genetic and functional characterization consists of the analysis of its expression according to:

Stages of cell development and maturation (different cell types)
Specific genotypes (mutations, transgenesis)
Loss of function (one or several associated genes)
Relationship with response to epigenetic factors (induced pathologies, restrictive diets, unfavorable environment, behavioral deficit)

Protein
Encapsulation

Protein encapsulation in bioactive liposomes

This consists of the encapsulation of a particular protein in vesicles formed by a biologically active lipid liposome of sphingolipidic origin.

Protein microencapsulation in liposomes

The liposomes generated by the biotechnology department present regenerative, anti-inflammatory, and neuronal properties, thus comprising an innovative form for the administration of DRUGS, NUTRACEUTICALS and BIOPRODUCTS. Besides, they are characterized by high biocompatibility, biodegradability and a total absence of biological toxicity indices.